ArticleMedical oncology (Northwood, London, England)2010
Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients.
Article in Medical oncology (Northwood, London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- The effects of lung and prostate cancer bone metastasis on serum osteoprotegerin levels: a meta-analysis.Scientific reports · 2015Pooled it
- The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer.International journal of clinical oncology · 2012Trial
- Clinical implications of serum GDF15 propeptide as a biomarker for bone metastasis across common solid tumors: a real-world multi-institutional study.Biomarker research · 2026Article
- Review
- Metabolic Health and Disease: A Role of Osteokines?Calcified tissue international · 2023Review
- Establishment of a regression model of bone metabolism markers for the diagnosis of bone metastases in lung cancer.World journal of surgical oncology · 2021Article
- Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value.Frontiers in oncology · 2021Review
- Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does the co-existence make the difference?Journal of thoracic disease · 2018Article
- High expression of USP22 predicts poor prognosis and advanced clinicopathological features in solid tumors: a meta-analysis.OncoTargets and therapy · 2018Article
- Monocyte chemotactic protein-1 deficiency attenuates and high-fat diet exacerbates bone loss in mice with Lewis lung carcinoma.Oncotarget · 2017Article
- Progress in the research on the mechanism of bone metastasis in lung cancer.Molecular and clinical oncology · 2016Article
- Correlation between lung neoplasm and serum level of osteopontin: A meta-analysis.Biomedical reports · 2016Article
- Serum sRANKL and sRANKL/OPG ratio: Novel biomarkers in non-small cell lung cancer.Oncology letters · 2016Article
- Loss of RUNX3 expression promotes cancer-associated bone destruction by regulating CCL5, CCL19 and CXCL11 in non-small cell lung cancer.The Journal of pathology · 2015Article
- Diagnostic and prognostic validity of serum bone turnover markers in bone metastatic non-small cell lung cancer patients.Journal of bone oncology · 2015Article
- Diagnostic value of bone-specific alkaline phosphatase in lung carcinoma patients with bone metastases: a meta-analysis.International journal of clinical and experimental medicine · 2015Article
- The association between osteopontin and survival in non-small-cell lung cancer patients: a meta-analysis of 13 cohorts.OncoTargets and therapy · 2015Article
- Bone metastases: When and how lung cancer interacts with bone.World journal of clinical oncology · 2014Review
- Emerging lung cancer therapeutic targets based on the pathogenesis of bone metastases.International journal of cell biology · 2014Review
- Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to investigate several bone markers in Non-Small Cell Lung (NSCLC) and Small Cell Lung (SCLC) patients experiencing or not secondary bony disease. Fasting serum levels of bone formation, bone resorption, and osteoclastogenesis markers were determined in 22 NSCLC patients with bone metastases, 18 without bone metastasis, and 28 SCLC patients. A total of 29 healthy volunteers were also included in the study. Decreased osteocalcin (OC) serum levels and increased osteopontin and ligand of the receptor of nuclear factor kB (RANKL) serum levels were detected in NCSLC patients with bone metastases while increased C-terminal cross-linking telopeptide of type I collagen and increased RANKL/OPG (osteoprotegerin) ratio were detected in SCLC patients. Increased serum levels of OPG were observed in all lung cancer patients. OPG may be actively involved in the development of lung cancer metastasis. Furthermore, OC, OPN, and RANKL in NSCLC and CTX and RANKL in SCLC patients may also have a broader role in the pathogenesis and spread of lung cancer. They also provide useful information in identifying the group of patients that may benefit from a more rigorous treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.